Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Financing Activities (2018 - 2025)

10x Genomics (TXG) has disclosed Cash from Financing Activities for 8 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 50.37% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, down 37.67% year-over-year, with the annual reading at $6.8 million for FY2025, 37.67% down from the prior year.
  • Cash from Financing Activities hit $2.2 million in Q4 2025 for 10x Genomics, up from $617000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $16.2 million in Q2 2021 to a low of -$3.4 million in Q1 2023.
  • Historically, Cash from Financing Activities has averaged $4.1 million across 5 years, with a median of $3.9 million in 2023.
  • Biggest five-year swings in Cash from Financing Activities: crashed 241.25% in 2023 and later soared 295.51% in 2025.
  • Year by year, Cash from Financing Activities stood at $8.9 million in 2021, then plummeted by 43.83% to $5.0 million in 2022, then increased by 12.24% to $5.6 million in 2023, then fell by 19.53% to $4.5 million in 2024, then tumbled by 50.37% to $2.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for TXG at $2.2 million in Q4 2025, $617000.0 in Q3 2025, and $3.5 million in Q2 2025.